Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT

SIMPLE SUMMARY: Although a significant improvement has been achieved in the management of metastatic neuroendocrine tumor (NET), disease progression is observed in 20–30% of patients treated with peptide receptor radionuclide therapy (PRRT). Therefore, the early identification of patients who are at...

Descripción completa

Detalles Bibliográficos
Autores principales: Durmo, Rexhep, Filice, Angelina, Fioroni, Federica, Cervati, Veronica, Finocchiaro, Domenico, Coruzzi, Chiara, Besutti, Giulia, Fanello, Silvia, Frasoldati, Andrea, Versari, Annibale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833820/
https://www.ncbi.nlm.nih.gov/pubmed/35158862
http://dx.doi.org/10.3390/cancers14030592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833820/
https://www.ncbi.nlm.nih.gov/pubmed/35158862
http://dx.doi.org/10.3390/cancers14030592

Ejemplares similares